Aclaris Therapeutics to Announce First Quarter 2024 Financial Results On May 7, 2024 and to Provide Corporate Update
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results On May 7, 2024 and to Provide Corporate Update
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets.
賓夕法尼亞州韋恩，2024年4月30日（環球新聞專線）——專注於開發免疫炎症性疾病新候選藥物的臨床階段生物製藥公司Aclaris Therapeutics, Inc.（納斯達克股票代碼：ACRS）今天宣佈，將在美國金融市場收盤後，於2024年5月7日星期二公佈2024年第一季度的財務業績。
Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcast live over the internet and can be accessed by logging into the "Investors" page of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. The webcast will be archived for at least 30 days on the Aclaris website.
管理層將在美國東部時間當天下午 5:00 舉行電話會議，提供公司最新情況。電話會議將通過互聯網進行網絡直播，可以通過登錄Aclaris Therapeutics網站的 “投資者” 頁面進行訪問， www.aclaristx.com，在活動之前。該網絡直播將在Aclaris網站上存檔至少30天。
About Aclaris Therapeutics, Inc.
關於 Aclaris Therapeutics, Inc
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics, Inc. 是一家處於臨床階段的生物製藥公司，正在開發一系列新型候選藥物，以滿足缺乏令人滿意的治療選擇的免疫炎症性疾病患者的需求。該公司擁有多階段候選藥物組合，由探索蛋白激酶調節的強大研發引擎提供支持。欲了解更多信息，請訪問 www.aclaristx.com。
Aclaris Therapeutics Contact:
Aclaris 治療聯繫人：
Source: Aclaris Therapeutics, Inc.
來源：Aclaris Therapeutics, Inc.